Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap Up - Time to Buy?

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $20.58, but opened at $22.32. Catalyst Pharmaceuticals shares last traded at $22.61, with a volume of 323,057 shares.

Analysts Set New Price Targets

Several research firms have commented on CPRX. Truist Financial lifted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, November 11th. Stephens reaffirmed an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Robert W. Baird lifted their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $32.50.

Remove Ads

Catalyst Pharmaceuticals Price Performance

The firm has a fifty day moving average of $22.24 and a two-hundred day moving average of $21.45. The stock has a market capitalization of $2.66 billion, a P/E ratio of 18.92, a P/E/G ratio of 3.31 and a beta of 0.80.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now owns 686,996 shares in the company, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of large investors have recently modified their holdings of CPRX. Park Square Financial Group LLC purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $29,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $3,733,000. Armis Advisers LLC acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $306,000. Mackenzie Financial Corp lifted its holdings in Catalyst Pharmaceuticals by 132.9% in the fourth quarter. Mackenzie Financial Corp now owns 34,531 shares of the biopharmaceutical company's stock valued at $721,000 after acquiring an additional 19,705 shares during the period. Finally, Castlekeep Investment Advisors LLC acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $1,775,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.